REG - MaxCyte, Inc. MaxCyte, Inc. - MXCR - Change of Name of Nominated Adviser and Broker

MaxCyteAnnouncement

09/07/2024 09:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240709:nRSI6718Va&default-theme=true

RNS Number : 6718V  MaxCyte, Inc.  09 July 2024

 

MaxCyte, Inc.

("MaxCyte" or the "Company")

 

Change of Name of Nominated Adviser and Broker

 

ROCKVILLE, MD, July 9, 2024: MaxCyte Inc., (NASDAQ: MXCT; LSE: MXCT),
a leading, cell-engineering focused company providing enabling platform
technologies to advance the discovery, development, and commercialization of
next-generation cell therapeutics and to support innovative, cell-based
research, announces that following the completion of the merger between
Panmure Gordon (UK) Limited and Liberum Capital Limited, the Company's
Nominated Adviser and Joint Broker has changed its name to Panmure Liberum
Limited with immediate effect.

 

  MaxCyte Contacts:

 

 US IR Adviser

 Gilmartin Group                               +1 415-937-5400

 David Deuchler, CFA                           ir@maxcyte.com (mailto:ir@maxcyte.com)

 Nominated Adviser and Joint Corporate Broker

 Panmure Liberum Limited                       +44 (0)20 7886 2500

 Emma Earl / Freddy Crossley

 Corporate Broking

 Rupert Dearden

 UK IR Adviser                                 +44 (0)203 709 5700

 ICR Consilium                                 maxcyte@consilium-comms.com (mailto:maxcyte@consilium-comms.com)

 Mary-Jane Elliott

 Chris Welsh

 

About MaxCyte

 

At MaxCyte, we pursue cell engineering excellence to maximize the potential of
cells to improve patients' lives. We have spent more than 20 years honing our
expertise by building best-in-class platforms, perfecting the art of the
transfection workflow, and venturing beyond today's processes to innovate
tomorrow's solutions. Our ExPERT™ platform, which is based on our Flow
Electroporation® technology, has been designed to support the rapidly
expanding cell therapy market and can be utilized across the continuum of the
high-growth cell therapy sector, from discovery and development through
commercialization of next-generation, cell-based medicines. The ExPERT family
of products includes: four instruments, the ATx™, STx™, GTx™ and VLx™;
a portfolio of proprietary related processing assemblies or disposables; and
software protocols, all supported by a robust worldwide intellectual property
portfolio. By providing our partners with the right technology, as well as
technical and regulatory support, we aim to guide them on their journey to
transform human health. Learn more at maxcyte.com (https://maxcyte.com/) and
follow us on Twitter (https://twitter.com/MaxCyte_info) and LinkedIn
(https://www.linkedin.com/company/maxcyte-inc-/) .

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  APPEAPXNEFALEEA